RMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ResMed Inc (RMD) is not a strong buy at the moment for a long-term beginner investor. While the company has demonstrated solid financial performance and positive analyst sentiment, the technical indicators suggest a bearish trend, and options data indicates bearish sentiment as well. Given the investor's preference for long-term investments, it may be better to wait for a more favorable technical setup or stronger bullish signals before entering the position.
The technical indicators for RMD are bearish. The MACD histogram is negative and expanding downward, RSI is neutral but leaning toward oversold territory, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock is trading below the pivot level of 255.498, with support at 250.467 and resistance at 260.529.
Strong financial performance in Q2 2026, with revenue up 10.98% YoY, net income up 13.92% YoY, and EPS up 14.53% YoY.
Positive analyst sentiment, with multiple price target increases and buy/outperform ratings from firms like Citi, KeyBanc, and RBC Capital.
Bearish technical indicators, including negative MACD and bearish moving averages.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
Options data indicating bearish sentiment with high put-call ratios.
Lack of recent congress trading data or influential figure involvement.
In Q2 2026, ResMed reported strong financial growth: Revenue increased by 10.98% YoY to $1.42 billion, net income rose by 13.92% YoY to $392.59 million, EPS grew by 14.53% YoY to 2.68, and gross margin improved by 5.52% YoY to 60.93%.
Analysts have generally positive sentiment toward RMD. Citi raised the price target to $345 with a Buy rating, and KeyBanc increased the target to $302 with an Overweight rating. RBC Capital also raised the target to $314 with an Outperform rating. However, some firms like Piper Sandler and Baird maintain Neutral ratings, citing modest growth and potential risks.
